Lobaplatin combined floxuridine/pirarubicin-based transcatheter hepatic arterial chemoembolization for unresectable primary hepatocellular carcinoma.
OBJECTIVE
To assess the effect and safety of lobaplatin combinated floxuridine /pirarubicin in transcatheter hepatic arterial chemoembolization(TACE) of unresectable primary liver cancer.


METHODS
TACE combined with the chemotherapy regimen was used to treat 34 unresectable primary liver cancer patients. DSA/ MRI/CT/blood routine examinations were used to evaluate short term activity and toxicity after 4-5 weeks, the process being repeated if necessary.


RESULTS
Among the 34 cases, 1 (2.9%) showed a complete response, 21 (61.7%) a partial response, 8 (23.5%) stable disease, and 4 progressive disease, with a total effective rate of 67.6%. The content of alpha fetoprotein dropped by over 50% in 20 cases (58.8%). The rate of recovery was hepatalgia (88.2%), ascites (47.1%), appetite (55.9%), Performance Status(30.4%). The median follow-up time (MFT) was 281 days (63-558 days), and median progression-free survival was 118.5 days (95%, CI:88.8-148.2 days). Adverse reactions (III-IV grade) were not common, with only 4 cases of vomiting and 2 cases of thrombocytopenia (III grade).


CONCLUSIONS
Lobaplatin-based TACE is an effective and safe treatment for primary liver cancer.
Department of Interventional Therapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China E-mail : 1506425915@126.com, derekqyf@126.com.
Chang
C
Zhao
Xu-Jie
XJ
Wang
Song
S
Wang
Wei-Hua
WH
Feng
Lei
L
Shi
Chun-Peng
CP
Yu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D003503:Cyclobutanes / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006499:Hepatic Artery / Q000187:drug effects*; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage
D003503:Cyclobutanes; D009944:Organoplatinum Compounds; D005467:Floxuridine; D004317:Doxorubicin; C027260:pirarubicin; C066228:lobaplatin